Which generation of targeted drug is Pazopanib?

Pazopanib/Pazopanib is a second-generation targeted drug. Pazopanib/Pazopanib is suitable for the treatment of adult patients with advanced renal cell carcinoma (RCC). Pazopanib/Pazopanib is suitable for the treatment of adult patients with advanced soft tissue sarcoma (STS) who have previously received chemotherapy.

The most common adverse reactions (≥20%) among patients receivingpazopanib versus placebo were fatigue (65% vs. 48%), abdominal pain Diarrhea (59% vs. 15%), nausea (56% vs. 22%), weight loss ( pan>48%than15%), HTN (42%than6%) , decreased appetite (40% vs. 19%), hair color change (39% vs. 2%), vomiting.

Laboratory abnormalities occurred in more than 10% of STS patients and were more common (≥5%) in patients treated with pazopanib and placebo, including AST (51% vs. 22%), ALT (46% vs. 18%), glucose (45% vs. 35%), alkaline phosphatase (32% vs. 23%), total bilirubin (29 % vs. 7%) and potassium (16% vs. 11%) increased; albumin (34% vs. 21%) and sodium (31% vs. 20%) decreased; leukopenia (44% vs. 15%), lymphopenia (43% vs. 36%), thrombocytopenia (36% vs. 6%), and neutropenia (33% vs. 7%). There are generic drugs in Bangladesh, and the retail price of Bangladesh Yaopin International Pharmaceutical is about 600 yuan for 30 tablets of 200 mg. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.